Introduction
Infection-related preterm birth (PTB) is more common at early gestations and is associated with significant neonatal mortality and morbidity (1) and major healthcare costs (2) . The presence of abnormal vaginal microbiota in early pregnancy is associated with a five-fold increased risk of late miscarriage and early PTB (3) . Accordingly, it is logical to consider the use of antibiotics for the prevention of infection-related PTB (4) . However, antibiotic studies have varied by antibiotic class and dose, inclusion of risk groups, diagnostic methods, degrees of abnormal vaginal colonization, routes of antibiotic administration, gestational age at time of treatment, host susceptibilities and hence host response, outcome parameters and definitions of success (4) . Although individual studies have found benefit of antibiotic intervention for the prevention of PTB, in meta-analyses these effects have been negated by the inclusion of large, methodologically flawed studies with negative results and by placing undue reliance on studies which: (i) used inappropriate antibiotics not recommended for the treatment of bacterial vaginosis (BV); (ii) used antibiotics too late in pregnancy to influence outcome, or (iii) included women whose risk of PTB was not related to vaginal dysbiosis and hence unlikely to respond to antibiotics. As a result, many clinicians erroneously consider that any antibiotic given at any time in pregnancy to any woman at risk of PTB will be unhelpful and cause more harm than good.
systematic review
A more focused systematic review and meta-analysis has demonstrated that clindamycin, used in women whose risk of PTB is due to bacterial vaginosis, and used early in pregnancy (<22 completed weeks of gestation) before irreversible inflammatory damage has occurred, can reduce the rate of PTB by 40% and late miscarriage by 80% (5) . Secondary outcomes revealed that, of those infants born preterm, 20% of those that received clindamycin had a baby <2500 g compared with 80% of those who received no treatment (p < 0.009). In addition, of those babies born preterm, there was a 32.5-day difference in mean gestational age in favor of antibiotics vs. no treatment (p < 0.024). This achievement should be measured against the fact that between 22 and 26 completed weeks of gestation, every day of delay in delivery results in a 3% increase in survival (6) . There was a statistically significant 86% reduction in delivery before 33 completed weeks of gestation for those who received antibiotics. In women with the worst degree of vaginal dysbiosis (Nugent Score on Gram stain = 10) (7), the rate of late miscarriage and PTB for those who received clindamycin was 5.4% compared with 35.7% for placebo (5) . Compared with those women in whom BV was cured, women with persistent BV were three times more likely to deliver preterm, and in those with cured but recurrent BV, the risk of PTB was 10 times that of women cured of BV with no recurrence (8) .
Rescreening and retreating with clindamycin
Using stringent diagnostic criteria (BV on Nugent score together with all four elements of Amsel's composite clinical criteria) (7, 9) , 70.8% of women who received clindamycin vaginal cream (CVC) to treat BV during pregnancy were cured or improved at 20-24 days post treatment compared with only 12% in a placebo group. Recurrence rates in those CVC patients successfully treated were approximately 6% at 6 weeks post baseline and 10% at 28-34 weeks. Of those women who failed to respond to the first 3-day course of CVC and who were retreated with a 7-day course of CVC, 32.6% and 51.2% were cured or improved at 20-24 days post retreatment and at 28-34 weeks' gestation, respectively (10) . Accordingly, rescreening and retreatment for BV in pregnancy is helpful as an initial course of CVC cured or improved BV in 88% of women, and a second course 3-6 weeks later still cured or improved BV in 50% of those who still had the condition (11) .
DSOG clinical recommendations
In contrast, the recent Danish clinical recommendations (produced by a guideline group within the DSOG) on the treatment of BV in pregnancy recommended against the use of clindamycin to reduce the risk of PTB (12) . After careful analysis, we believe that this recommendation was reached erroneously on the basis of two flawed decisions relating to study inclusion criteria, and as a result, the recommendation provides incorrect advice to the obstetric community on the effectiveness of clindamycin for this indication. While the first author (R.F.L.) was acknowledged and thanked by the authors for his expert advice, this should not be misconstrued as tacit agreement; as the acknowledgement states, the recommendation is not necessarily an expression of his position towards the investigated Population, Intervention, Comparator and Outcome questions.
Our first concern relates to the use of 20 weeks of gestation as the cut-off for intervention. We accept that in any systematic review, categorical cut-off points are needed. However, these points are flexible and care must be taken to ensure that important studies are not arbitrarily excluded. The 20-week cut-off employed by Haahr et al. resulted in the exclusion of a trial, which is probably the most significant study on the use of clindamycin in early pregnancy for the prevention of PTB (13) . Undoubtedly, had the cut-off point been set at 22 weeks and this study included, the data shown in figure 4 of the DSOG guidelines group (12) would have demonstrated a statistically significant reduction in the incidence of PTB (5).
PREMEVA1 study
Our second concern relates to the inclusion of data from an unpublished study (PREMEVA1) presented in abstract form in 2013 at the 34th Annual Meeting of the Society for Materno-Fetal Medicine Meeting, New Orleans, USA (14) . In the analyses in figures 3 and 4 of Haahr et al. (12) , the PREMEVA1 study constituted the major weighting of both figures (23 and 54%, respectively). This is a major concern because, as far as we and the DSOG guidelines group can determine, the study has never been published following peer review, despite the fact that the data were presented more than 3 years ago. In a recent review (4), the existence and negative findings of the study were acknowledged with the caution that until the details of the PREMEVA1 study were fully available, the significance of the findings was uncertain and "these should not be used to influence guidelines" (4), yet the DSOG guidelines group have chosen to use these data.
When the PREMEVA1 abstract was published, the conclusion of many experts was that the lack of efficacy of clindamycin might be explained by poor diagnosis of BV. This has since been confirmed in a personal communication from one of the co-authors of the PREMEVA1 study. The full manuscript will not be submitted for review until the diagnosis of BV can be rechecked using molecularly based techniques, though this may also be suboptimal as the investigators plan to use organic material from the original Gram-stain slides. Clearly, the data from this study should not be included when formulating clinical recommendations or guidelines.
We acknowledge that Haahr et al. carried out a subgroup analysis with the PREMEVA1 study excluded (figure 5 in Haahr et al.) (12) . In this subgroup analysis, the use of clindamycin significantly reduced the incidence of PTB, which is testament to the effect of the erroneous inclusion of PREMEVA1. However, the recommendations stated in the Abstract and "Key Message" box are based on analysis with the PREMEVA1 study included, and the significance of the subgroup analysis will be lost on the majority who do not read the recommendations in full. Accordingly, as with many other meta-analyses, the clinical recommendation will be cited erroneously as evidence that any antibiotic, administered to any woman, at any stage in pregnancy does not prevent PTB, when with respect to the early use of clindamycin in women with objective evidence of vaginal dysbiosis, the evidence is robust and shows that this is clearly not the case (4, 5) .
Minor comments
We highlight two other issues of minor concern. First, the incidence of PTB in the presence of BV is cited as being doubled, but when screening is performed before 20 weeks of gestation, the incidence of late miscarriage or PTB before 34 completed weeks of gestation rises 5.5-to 6.9-fold (15) . Second, in figure 1 of Haahr et al. (12) , the population of one study (16) is included as low-risk, yet 85% of the women in the study were African American or Hispanic (17) . African American women have twice the risk of PTB (50% of which is thought to be due to infection) and three times the incidence of BV compared with white women in the USA, which means that they are not low risk.
AOGS Editorial
In a subsequent Editorial in AOGS (18) (which we commend as a balanced overview of the evaluation of guidelines, the quality of the evidence and the strength of recommendation), the Editors called for objectivity in the production of guidelines and differentiated these from consensus statements, between which there is a fine distinction. To create recommendations, the clinical recommendations of the DSOG guidelines group used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (http://www. gradeworkinggroup.org), which is not without its own challenges, not the least of which is that it requires training and can result in the quality of evidence being graded as "low" but the recommendation being "strong". The recommendations of the DSOG guidelines group were a subject of considerable discussion among the authors, reviewers and editors due to concerns over the discrepancy between the evidence and the strength of the recommendations before the manuscript was eventually accepted as a systematic review.
Clindamycin vs. metronidazole
For the treatment of BV, oral or vaginal metronidazole or clindamycin is recommended by the CDC (19) . However, when considering the optimal antibiotic for the prevention of PTB of infectious etiology, there may be more logic in using clindamycin than metronidazole. Like macrolide antibiotics, clindamycin has anti-inflammatory properties (20) and has a broader range of activity against BV than metronidazole. Metronidazole is inactive in vitro against organisms associated with BV and has little or no activity against aerobic organisms. However, metronidazole is active in vivo, which suggests two possible mechanisms: either BV-related organisms may be sensitive to the hydroxymetabolite of metronidazole or, more likely, metronidazole acts indirectly through synergism, killing anaerobes that provide substrate to BV-related organisms such as Gardnerella vaginalis or Atopobium vaginae (21) . Culture-independent techniques have demonstrated that BV is not a single entity but a syndrome of different communities that may be dominated by anaerobes, a combination of G. vaginalis and A. vaginae, or other abnormal subtypes of mixed organisms (22) . Accordingly, it may be that those subtypes of BV in which anaerobes are dominant are more successfully treated by metronidazole whereas clindamycin may be active against both metronidazole-sensitive subtypes and other BV subtypes with different microbial communities. Finally, the case in favor of metronidazole is often made because metronidazole conserves vaginal lactobacilli, whereas clindamycin eradicates them. However, phage virus colonization of lactobacilli is associated with BV, and it is postulated that dietary acquired phage viruses may be induced to become lytic by factors related to sexual activity and smoking (which is a risk factor for BV), or that Lactobacillus phages may be directly inoculated into the vagina from sexual partners (23) . If phage virus colonization of lactobacilli is present, metronidazole may perpetuate rather than cure BV, whereas the opposite would be true with clindamycin.
Conclusion
The evidence pertaining to the early use of clindamycin for the treatment of BV in pregnancy to reduce the risk of infection-related PTB is robust (4, 5) . The clinical recommendations of the DSOG guidelines group (12) are erroneous due to the inclusion of a flawed unpublished study (14) and by the exclusion of an important study (13) . Without these errors, the conclusions would be different. The recommendations also fail to incorporate the recent findings that screening and treating of vulvovaginal candidiasis, trichomoniasis (treated appropriately) and BV (treated with CVC) reduced the rate of PTB and low birthweight from 22.3 to 20% in controls to 9.7 and 8.4%, respectively (p = 0.001) (24) . We argue that the clinical recommendations (12) should be revoked and the PREMEVA1 study (14) should not be used to influence guidelines or clinical recommendations.
